AU2002336985B2 - Use of C2-substituted Indane-1-one systems for producing medicaments for the prophylaxis or treatment of obesity - Google Patents

Use of C2-substituted Indane-1-one systems for producing medicaments for the prophylaxis or treatment of obesity Download PDF

Info

Publication number
AU2002336985B2
AU2002336985B2 AU2002336985A AU2002336985A AU2002336985B2 AU 2002336985 B2 AU2002336985 B2 AU 2002336985B2 AU 2002336985 A AU2002336985 A AU 2002336985A AU 2002336985 A AU2002336985 A AU 2002336985A AU 2002336985 B2 AU2002336985 B2 AU 2002336985B2
Authority
AU
Australia
Prior art keywords
alkyl
cycloalkyl
replaced
fluorine
cooh
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002336985A
Other languages
English (en)
Other versions
AU2002336985A1 (en
Inventor
Martin Bickel
Matthias Gossel
Gerhard Jaehne
Volker Krone
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Sanofi Aventis Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland GmbH filed Critical Sanofi Aventis Deutschland GmbH
Publication of AU2002336985A1 publication Critical patent/AU2002336985A1/en
Assigned to SANOFI-AVENTIS DEUTSCHLAND GMBH reassignment SANOFI-AVENTIS DEUTSCHLAND GMBH Request for Assignment Assignors: AVENTIS PHARMA DEUTSCHLAND GMBH
Application granted granted Critical
Publication of AU2002336985B2 publication Critical patent/AU2002336985B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2002336985A 2001-08-31 2002-08-17 Use of C2-substituted Indane-1-one systems for producing medicaments for the prophylaxis or treatment of obesity Ceased AU2002336985B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10142668.2 2001-08-31
DE10142668A DE10142668A1 (de) 2001-08-31 2001-08-31 Verwendung von C2-substituierten Indan-1-on-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
PCT/EP2002/009208 WO2003020256A1 (de) 2001-08-31 2002-08-17 Verwendung von c2-substituierten indan-1-on-systemen zur herstellung von medikamenten zur prophylaxe oder behandlung von obesitas

Publications (2)

Publication Number Publication Date
AU2002336985A1 AU2002336985A1 (en) 2003-06-05
AU2002336985B2 true AU2002336985B2 (en) 2006-11-16

Family

ID=7697238

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002336985A Ceased AU2002336985B2 (en) 2001-08-31 2002-08-17 Use of C2-substituted Indane-1-one systems for producing medicaments for the prophylaxis or treatment of obesity

Country Status (10)

Country Link
US (1) US6946492B2 (https=)
EP (1) EP1424999A1 (https=)
JP (1) JP4342306B2 (https=)
AU (1) AU2002336985B2 (https=)
CA (1) CA2458555A1 (https=)
DE (1) DE10142668A1 (https=)
IL (2) IL160607A0 (https=)
MX (1) MXPA04001853A (https=)
PE (1) PE20030336A1 (https=)
WO (1) WO2003020256A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101746867B1 (ko) * 2009-01-26 2017-06-14 타이페이 메디컬 유니이버시티 당뇨 및 비만을 치료하기 위한 프테로신 화합물의 용도
CN103333144B (zh) * 2013-06-17 2014-12-10 温州大学 一种2-硫基-3-卤代苯并呋喃化合物及其合成方法和用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001002373A1 (fr) * 1999-07-06 2001-01-11 Merck Patent Gmbh Dihydrobenzodiazepines et leur utilisation dans le traitement de dyslipidemies

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0009554B1 (de) * 1978-07-27 1983-04-27 Schering Aktiengesellschaft Indanyl-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Präparate
WO1989003681A1 (en) * 1987-10-19 1989-05-05 Pfizer Inc. Substituted tetralins, chromans and related compounds in the treatment of asthma
WO1997020802A1 (en) * 1995-12-06 1997-06-12 Venantius Limited Indane dimer compounds and their pharmaceutical use
AU727775B2 (en) 1996-01-17 2000-12-21 Novo Nordisk A/S Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use
IL128332A0 (en) 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
IL127296A (en) 1996-12-31 2003-01-12 Reddy Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them
PL338013A1 (en) 1997-07-16 2000-09-25 Novo Nordisk As Derivatives of condensed 1,2,4-thiadiazine, their production and application
EA004229B1 (ru) * 1999-03-01 2004-02-26 Пфайзер Продактс Инк. Оксаминовые кислоты и их производные в качестве лигандов тиреоидных рецепторов
EP1078632A1 (en) 1999-08-16 2001-02-28 Sanofi-Synthelabo Use of monoamine oxydase inhibitors for the manufacture of drugs intended for the treatment of obesity

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001002373A1 (fr) * 1999-07-06 2001-01-11 Merck Patent Gmbh Dihydrobenzodiazepines et leur utilisation dans le traitement de dyslipidemies

Also Published As

Publication number Publication date
JP2005503396A (ja) 2005-02-03
CA2458555A1 (en) 2003-03-13
JP4342306B2 (ja) 2009-10-14
DE10142668A1 (de) 2003-03-20
IL160607A (en) 2011-03-31
US6946492B2 (en) 2005-09-20
IL160607A0 (en) 2004-07-25
EP1424999A1 (de) 2004-06-09
WO2003020256A1 (de) 2003-03-13
US20030134882A1 (en) 2003-07-17
PE20030336A1 (es) 2003-05-19
MXPA04001853A (es) 2004-06-15

Similar Documents

Publication Publication Date Title
AU2002333447B2 (en) Use of polysubstituted indan-1-ol systems for producing drugs in the prophylaxis or treatment of obesity
AU2002333448B2 (en) Derivatives of C2-substituted indan-1-ol systems, methods for the production thereof and their use as medicaments
AU2002336985B2 (en) Use of C2-substituted Indane-1-one systems for producing medicaments for the prophylaxis or treatment of obesity
AU2002342615B2 (en) Use of derivatives of C2-substituted indan-1-ol systems for producing medicaments for the prophylaxis or the treatment of obesity
AU2002336984B2 (en) Use of C2-substituted Indane-1-ol systems for producing medicaments for the prophylaxis or treatment of obesity
AU2002336982B2 (en) C2-disubstituted Indane-1-ol systems, method for their production and their use as medicaments
AU2002336085B2 (en) C2-substituted Indane-1-ones and their derivatives, method for their production and their use as medicaments
AU2002336983B2 (en) C2-disubstituted Indane-1-ones and their derivatives, method for their production and their use as medicaments
AU2002333449B2 (en) C2-substituted indane-1-ols and their derivatives, method for their production and their use as medicaments
AU2002329252B2 (en) Polysubstituted indan-1-ol systems, method for the production and use thereof as drugs

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH

Free format text: FORMER APPLICANT(S): AVENTIS PHARMA DEUTSCHLAND GMBH

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired